Drug Trial Radar · NCT06597422
A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Oct 20, 2024
Primary completion
Jan 23, 2025
Study completion Jan 23, 2025
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial is a Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of STSP-0902 ophthalmic solution in healthy subjects following single and multiple administrations. The study plans to enroll 80 healthy subjects and is divided into three stages: the single-dose study stage, the multiple-dose study stage, and the tear PK study stage. The single-dose and multiple-dose study stages are randomized, double-blind, placebo-controlled, dose-escalation designs, while the tear PK study stage is a single-dose, open-label design.
Conditions
- Neurotrophic Keratitis
Interventions
STSP-0902 ophthalmic solutionDrug
Eye drop, single dose
STSP-0902 PlaceboDrug
Eye drop, single dose
STSP-0902 ophthalmic solutionDrug
Eye drop, three times daily for a total of 8 days
STSP-0902 ophthalmic solutionDrug
Eye drop, six times daily for a total of 8 days
STSP-0902 PlaceboDrug
Eye drop, multiple doses
STSP-0902 ophthalmic solutionDrug
Eye drop, single dose, tear samples will be collected
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events related to study drugTime frame: Baseline to Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.